Molecular imaging firm Blue Earth Diagnostics announced exclusive manufacturing and distribution agreements with radiopharmaceutical supplier Iason for its PET imaging agent Axumin (fluciclovine F-18) in Poland.
Iason will bring Axumin to market in Poland through its manufacturing site in Mszczonów.
Blue Earth received marketing authorization for Axumin from the European Commission in May 2017. The agent is for use in PET imaging to detect prostate cancer recurrence that is suspected based on elevated blood prostate-specific antigen (PSA) levels after primary curative treatment.
Blue Earth is working to build a network of authorized and approved manufacturing locations across Europe, the firm said. It now has six manufacturing and distribution agreements for Axumin in 17 European countries.